中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Repurposing of Kinase Inhibitors for Treatment of COVID-19

文献类型：期刊论文

作者Weisberg, Ellen1,2; Parent, Alexander1,2; Yang, Priscilla L.3,4; Sattler, Martin1,2,5; Liu, Qingsong6; Liu, Qingwang6; Wang, Jinhua7; Meng, Chengcheng1; Buhrlage, Sara J.8; Gray, Nathanael7
刊名PHARMACEUTICAL RESEARCH
出版日期2020-08-10
卷号37
ISSN号0724-8741
关键词Coronavirus SARS-CoV-2 SARS-CoV MERS-CoV kinase inhibitors pharmacokinetics antiviral therapy COVID-19
DOI10.1007/s11095-020-02851-7
通讯作者Weisberg, Ellen(ellen_weisberg@dfci.harvard.edu)
英文摘要The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community. In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening. There are numerous protein kinases associated with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity. Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.
WOS关键词GROWTH-FACTOR RECEPTOR ; CELL LUNG-CANCER ; RESPIRATORY SYNDROME CORONAVIRUS ; HEPATITIS-C VIRUS ; CHRONIC MYELOID-LEUKEMIA ; VENTILATOR-ASSOCIATED PNEUMONIA ; PLACEBO-CONTROLLED TRIAL ; ABL TYROSINE KINASE ; I DOSE-ESCALATION ; IMATINIB MESYLATE
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
出版者SPRINGER/PLENUM PUBLISHERS
WOS记录号WOS:000557903900001
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/44969]  
专题中国科学院合肥物质科学研究院
通讯作者Weisberg, Ellen
作者单位1.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
2.Harvard Med Sch, Dept Med, Boston, MA 02115 USA
3.Dana Farber Canc Inst, Dept Canc Cell Biol, Boston, MA 02115 USA
4.Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA
5.Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA
6.Chinese Acad Sci, High Magnet Field Lab, Hefei, Anhui, Peoples R China
7.Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
8.Harvard Med Sch, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02215 USA
推荐引用方式
GB/T 7714		 Weisberg, Ellen,Parent, Alexander,Yang, Priscilla L.,et al. Repurposing of Kinase Inhibitors for Treatment of COVID-19[J]. PHARMACEUTICAL RESEARCH,2020,37.
APA Weisberg, Ellen.,Parent, Alexander.,Yang, Priscilla L..,Sattler, Martin.,Liu, Qingsong.,...&Griffin, James D..(2020).Repurposing of Kinase Inhibitors for Treatment of COVID-19.PHARMACEUTICAL RESEARCH,37.
MLA Weisberg, Ellen,et al."Repurposing of Kinase Inhibitors for Treatment of COVID-19".PHARMACEUTICAL RESEARCH 37(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。